Table 2 Characteristics of the study population
Toxic liver disease (N = 26) | Hepatic failure (N = 58) | Jaundice (N = 31) | ||
|---|---|---|---|---|
n (%) | n (%) | n (%) | ||
Sex | Male | 11 (42%) | 36 (62%) | 15 (48%) |
Female | 15 (58%) | 22 (38%) | 16 (52%) | |
Age (years) | 0–17 | 4 (15%) | 3 (5%) | 0 |
18–39 | 5 (19%) | 4 (7%) | 1 (3%) | |
40–59 | 12 (46%) | 14 (24%) | 11 (35%) | |
60–69 | 5 (19%) | 24 (41%) | 10 (32%) | |
> 70 | 0 | 13 (22%) | 9 (29%) | |
Calendar year of diagnosis | 2005–2007 | 6 (23%) | 1 (2%) | 4 (13%) |
2008–2010 | 5 (19%) | 18 (31%) | 8 (26%) | |
2011–2012 | 10 (38%) | 17 (29%) | 9 (29%) | |
2013–2014 | 5 (19%) | 22 (38%) | 10 (32%) | |
Any malignancy 10 years prior to liver disorder diagnosis | 16 (62%) | 39 (67%) | 26 (84%) | |
Antifungal azole drug prior to liver disorder diagnosis | Ketoconazole | 2 (8%) | 4 (7%) | 1 (3%) |
Fluconazole | 23 (88%) | 45 (78%) | 29 (94%) | |
Itraconazole | 1 (4%) | 3 (5%) | 0 | |
Voriconazole | 0 | 5 (9%) | 1 (3%) | |
Posaconazole | 0 | 1 (2%) | 0 | |